Mechanistic Insights into the Effects of SREBP1c on Hepatic Stellate Cell and Liver Fibrosis
Overview
Molecular Biology
Authors
Affiliations
Sterol regulatory element-binding protein 1c (SREBP1c) plays key roles in maintenance of hepatic stellate cell (HSC) quiescence. The present researches investigated the mechanisms underlying the effects of SREBP1c on HSCs and liver fibrogenesis by HSC-targeted overexpression of the active SREBP1c using adenovirus in vitro and in vivo. Results demonstrated that SREBP1c exerted inhibitory effects on TAA-induced liver fibrosis. SREBP1c down-regulated TGFβ1 level in liver, reduced the receptors for TGFβ1 and PDGFβ, and interrupted the signalling pathways of Smad3 and Akt1/2/3 but not ERK1/2 in HSCs. SREBP1c also led to the decreases in the protein levels of the bromodomain-containing chromatin-modifying factor bromodomain protein 4, methionine adenosyltransferase 2B (MAT2B) and TIMP1 in HSCs. In vivo activated HSCs did not express cyclin D1 and cyclin E1 but SREBP1c down-regulated both cyclins in vitro. SREBP1c elevated PPARγ and MMP1 protein levels in the model of liver fibrosis. The effect of SREBP1c on MAT2B expression was associated with its binding to MAT2B1 promoter. Taken together, the mechanisms underlying the effects of SREBP1c on HSC activation and liver fibrosis were involved in its influences on TGFβ1 level, the receptors for TGFβ1 and PDGFβ and their downstream signalling, and the molecules for epigenetic regulation of genes.
Xin W, Zhou J, Peng Y, Gong S, Liao W, Wang Y Adv Sci (Weinh). 2024; 12(6):e2412233.
PMID: 39680752 PMC: 11809329. DOI: 10.1002/advs.202412233.
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis.
Chandrasekaran P, Weiskirchen R Int J Mol Sci. 2024; 25(2).
PMID: 38256181 PMC: 10815951. DOI: 10.3390/ijms25021109.
SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies.
Li N, Li X, Ding Y, Liu X, Diggle K, Kisseleva T Biomedicines. 2023; 11(12.
PMID: 38137501 PMC: 10740981. DOI: 10.3390/biomedicines11123280.
Yang L, Zhang B Evid Based Complement Alternat Med. 2022; 2022:1745244.
PMID: 35836833 PMC: 9276475. DOI: 10.1155/2022/1745244.
Lu Y, Zhang Z, Wang S, Qi Y, Chen F, Xu Y Stem Cell Reports. 2022; 17(3):599-615.
PMID: 35148846 PMC: 9039836. DOI: 10.1016/j.stemcr.2022.01.011.